Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Amsterdam, The Netherlands, May 29, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces...
-
Kiadis Submits Response to the European Medicines Agency's Day 180 Second List of Outstanding Issues
Amsterdam, The Netherlands, May 22, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced...
-
Collaboration will support Phase III clinical trial of cell therapy product ATIR101(TM) for blood cancers MINNEAPOLIS & AMSTERDAM, May 22, 2019 - Be The Match BioTherapies®, an organization...
-
Amsterdam, The Netherlands, 13 May 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a...
-
Amsterdam, The Netherlands, 30 April 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a...
-
Amsterdam, The Netherlands, April 17, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels:...
-
Kiadis to Acquire CytoSen Therapeutics, Inc. Transaction creates leader in cell-based cancer immunotherapy, with complementary T-cell and NK-cell...
-
Kiadis Pharma to present at upcoming investor conferences in April 2019 Amsterdam, The Netherlands, April 9, 2019 - Kiadis Pharma N.V. ("Kiadis...
-
Kiadis Pharma Announces Results of Extraordinary General Meeting of Shareholders Amsterdam, The Netherlands, March 29, 2019 -...
-
Kiadis Pharma Strengthens Management Team Dirk de Naeyer appointed Chief Operations Officer and Martine Nolan as Head of Quality Assurance,...